Ann: Mesoblast Provides Corporate Update and Q1 Financial Results, page-5

I see they mentioned the $500k in Milestone revenue for temcell, but not the $534k payment to Osiris as part of the contingent consideration? They also wrote off $9.5m of the remaining consideration payable to Osiris because

"In the three months ended September 30, 2017 a gain of $9.5 million was recognized on the remeasurement of contingent
consideration pertaining to the acquisition of assets from Osiris. This gain is a net result of changes to the key assumptions of
the contingent consideration valuation such as developmental timelines, product pricing, market penetration, market population
and the increase in valuation as the time period shortens between the valuation date and the potential settlement dates of
contingent consideration."

Doesn't suggest that Temcell is getting much traction...